ID   KKU-213B
AC   CVCL_M264
SY   KKU-M214; KKUM214; M214; KKU-214; KKU214
DR   JCRB; JCRB1556
DR   Wikidata; Q54900011
RX   PubMed=15884115;
RX   PubMed=16475706;
RX   PubMed=18714155;
RX   PubMed=21871105;
RX   PubMed=22926522;
RX   PubMed=25998688;
RX   PubMed=31077409;
RX   PubMed=32207095;
RX   PubMed=35640676;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a KKU-213A derivative (PubMed=32207095 and JCRB web site).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00592.
CC   Population: Southeast Asian; Thai.
CC   Doubling time: 22.68 +- 2.20 hours (PubMed=25998688); 24.5 +- 0.2 hours (PubMed=32207095).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: After JCRB found out that KKU-M156 and KKU-M214 were derived from KKU-M213, these three cell lines were renamed by the lab which established them: KKU-M213 became KKU-213A, KKU-M214 became KKU-M213B and KKU-M156 became KKU-M213C (PubMed=32207095).
CC   Discontinued: JCRB; JCRB1556; probable.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): PubMed=32207095
ST   Amelogenin: X
ST   CSF1PO: 9,13
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D18S51: 14
ST   D19S433: 13,14
ST   D21S11: 29
ST   D2S1338: 22,23,24
ST   D3S1358: 15
ST   D5S818: 9
ST   D7S820: 11
ST   D8S1179: 11,13
ST   FGA: 16,19
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M261 ! KKU-213A
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 02-05-24; Version: 18
//
RX   PubMed=15884115; DOI=10.3748/wjg.v11.i18.2748; PMCID=PMC4305909;
RA   Tepsiri N., Chaturat L., Sripa B., Namwat W., Wongkham S.,
RA   Bhudhisawasdi V., Tassaneeyakul W.;
RT   "Drug sensitivity and drug resistance profiles of human intrahepatic
RT   cholangiocarcinoma cell lines.";
RL   World J. Gastroenterol. 11:2748-2753(2005).
//
RX   PubMed=16475706;
RA   Panichakul T., Intachote P., Wongkajornsilp A., Sripa B., Sirisinha S.;
RT   "Triptolide sensitizes resistant cholangiocarcinoma cells to
RT   TRAIL-induced apoptosis.";
RL   Anticancer Res. 26:259-265(2006).
//
RX   PubMed=18714155; DOI=10.1159/000151541;
RA   Namwat N., Amimanan P., Loilome W., Jearanaikoon P., Sripa B.,
RA   Bhudhisawasdi V., Tassaneeyakul W.;
RT   "Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell
RT   lines.";
RL   Chemotherapy 54:343-351(2008).
//
RX   PubMed=21871105; DOI=10.1186/1476-4598-10-102; PMCID=PMC3173387;
RA   Obchoei S., Weakley S.M., Wongkham S., Wongkham C., Sawanyawisuth K.,
RA   Yao Q.-Z., Chen C.-Y.;
RT   "Cyclophilin A enhances cell proliferation and tumor growth of liver
RT   fluke-associated cholangiocarcinoma.";
RL   Mol. Cancer 10:102.1-102.15(2011).
//
RX   PubMed=22926522; DOI=10.1038/onc.2012.382; PMCID=PMC3869796;
RA   Kunkeaw N., Jeon S.H., Lee K., Johnson B.H., Tanasanvimon S.,
RA   Javle M., Pairojkul C., Chamgramol Y., Wongfieng W., Gong B.,
RA   Leelayuwat C., Lee Y.S.;
RT   "Cell death/proliferation roles for nc886, a non-coding RNA, in the
RT   protein kinase R pathway in cholangiocarcinoma.";
RL   Oncogene 32:3722-3731(2013).
//
RX   PubMed=25998688; DOI=10.3892/ijo.2015.3019;
RA   Wattanawongdon W., Hahnvajanawong C., Namwat N., Kanchanawat S.,
RA   Boonmars T., Jearanaikoon P., Leelayuwat C., Techasen A., Seubwai W.;
RT   "Establishment and characterization of gemcitabine-resistant human
RT   cholangiocarcinoma cell lines with multidrug resistance and enhanced
RT   invasiveness.";
RL   Int. J. Oncol. 47:398-410(2015).
//
RX   PubMed=31077409; DOI=10.1002/hep.30704;
RA   Sittithumcharee G., Suppramote O., Vaeteewoottacharn K.,
RA   Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M.,
RA   Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K.,
RA   Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P.,
RA   Pairojkul C., Wongkham S., Sampattavanich S., Okada S.,
RA   Jirawatnotai S.;
RT   "Dependency of cholangiocarcinoma on cyclin D-dependent kinase
RT   activity.";
RL   Hepatology 70:1614-1630(2019).
//
RX   PubMed=32207095; DOI=10.1007/s13577-020-00334-w;
RA   Sripa B., Seubwai W., Vaeteewoottacharn K., Sawanyawisuth K.,
RA   Silsirivanit A., Kaewkong W., Muisuk K., Dana P., Phoomak C.,
RA   Lert-itthiporn W., Luvira V., Pairojkul C., Teh B.T., Wongkham S.,
RA   Okada S., Chamgramol Y.;
RT   "Functional and genetic characterization of three cell lines derived
RT   from a single tumor of an Opisthorchis viverrini-associated
RT   cholangiocarcinoma patient.";
RL   Hum. Cell 33:695-708(2020).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//